var data={"title":"Risedronate: Drug information","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"drugTitle\">Risedronate: Drug information</div><div id=\"lexiTitleImg\"></div><div class=\"clear\"></div><div id=\"lcoSearchClickUrl\"><a href=\"http://online.lexi.com/lco/action/api/find/globalid/6916?utd=1\" target=\"_blank\">Access Lexicomp Online here.</a></div><div id=\"drugCopy\">Copyright 1978-2018 Lexicomp, Inc. All rights reserved.</div><div id=\"topicText\">(For additional information <a href=\"topic.htm?path=risedronate-patient-drug-information\" class=\"drug drug_patient\">see &quot;Risedronate: Patient drug information&quot;</a>)<br></br>For abbreviations and symbols that may be used in Lexicomp (<a href=\"image.htm?imageKey=DRUG%2F57469\" class=\"graphic graphic_table\">show table</a>)<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F218582\" class=\"list ubnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: US</span>\n    <ul>\n      <li>Actonel;</li>\n      <li>Atelvia</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F218583\" class=\"list cbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: Canada</span>\n    <ul>\n      <li>Actonel;</li>\n      <li>Actonel DR;</li>\n      <li>Apo-Risedronate;</li>\n      <li>Auro-Risedronate;</li>\n      <li>Dom-Risedronate;</li>\n      <li>JAMP-Risedronate;</li>\n      <li>Mylan-Risedronate;</li>\n      <li>PMS-Risedronate;</li>\n      <li>ratio-Risedronate;</li>\n      <li>Riva-Risedronate;</li>\n      <li>Sandoz-Risedronate;</li>\n      <li>Teva-Risedronate</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F218606\" class=\"ex_sect_xr thclist drugH1Div drugBrandNames\"><span class=\"drugH1\">Pharmacologic Category</span>\n    <ul>\n      <li>\n        Bisphosphonate Derivative</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F218586\" class=\"block doa drugH1Div\"><span class=\"drugH1\">Dosing: Adult</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Note:</b> Patients should receive supplemental calcium and vitamin D if dietary intake is inadequate. Consider discontinuing after 3 to 5 years of use for osteoporosis in patients at low-risk for fracture.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Paget disease of bone:</b> Oral: <i>Immediate release tablet:</i> 30 mg once daily for 2 months</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Note:</b> Re-treatment may be considered (following post-treatment observation of at least 2 months) if relapse occurs, or if treatment fails to normalize serum alkaline phosphatase. For re-treatment, the dose and duration of therapy are the same as for initial treatment. No data are available on more than one course of retreatment. The Endocrine Society guidelines suggest re-treatment may be required between 1 and 5 years (Singer, 2014).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Osteoporosis (postmenopausal):</b> Oral:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Immediate release tablet: Prevention and treatment: 5 mg once daily <b>or</b> 35 mg once weekly <b>or</b> 150 mg once monthly</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Delayed release tablet: Treatment: 35 mg once weekly</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Osteoporosis (males) treatment:</b> Oral: <i>Immediate release tablet:</i> 35 mg once weekly</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Osteoporosis (glucocorticoid-induced) prevention and treatment:</b> Oral: <i>Immediate release tablet:</i> 5 mg once daily</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">\n      <i>\n        <b>Missed doses:</b> Immediate release tablet:</i></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Once-weekly:</i> If a once-weekly dose is missed, it should be given the next morning after remembered; may then return to the original once-weekly schedule (original scheduled day of the week), however, do not give 2 doses on the same day.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Monthly (150 mg once monthly): </i>If 150 mg once-monthly dose is missed, it should be given the next morning after remembered if the next month's scheduled dose is &gt;7 days away. If the next month's scheduled dose is within 7 days, wait until the next month's scheduled dose. For either scenario, may then return to the original monthly schedule (original scheduled day of the month). Do not give &gt;150 mg within 7 days.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F218587\" class=\"block doe drugH1Div\"><span class=\"drugH1\">Dosing: Geriatric</span>\n    <p style=\"text-indent:0em;display:inline\">Refer to adult dosing.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F218588\" class=\"block dor drugH1Div\"><span class=\"drugH1\">Dosing: Renal Impairment</span>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;text-align:justify;\">CrCl &ge;30 mL/minute: No dosage adjustment necessary.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CrCl &lt;30 mL/minute: Use is not recommended</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F9565124\" class=\"block doh drugH1Div\"><span class=\"drugH1\">Dosing: Hepatic Impairment</span>\n    <p style=\"text-indent:0em;display:inline\">There are no dosage adjustments provided in the manufacturer's labeling (has not been studied). However, dosage adjustment unlikely because risedronate is not metabolized by the liver.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F218556\" class=\"block foc drugH1Div\"><span class=\"drugH1\">Dosage Forms</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Tablet, Oral, as sodium: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Actonel: 5 mg, 30 mg, 35 mg</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Actonel: 150 mg [contains fd&amp;c blue #2 aluminum lake]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 5 mg, 30 mg, 35 mg, 150 mg</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Tablet Delayed Release, Oral, as sodium: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Atelvia: 35 mg [contains edetate disodium]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 35 mg</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F218541\" class=\"block geq drugH1Div\"><span class=\"drugH1\">Generic Equivalent Available (US)</span>\n    <p style=\"text-indent:0em;display:inline\">Yes</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F46548992\" class=\"block foccan drugH1Div\"><span class=\"drugH1\">Dosage Forms: Canada</span>\n    <p style=\"text-indent:0em;display:inline\">Information with regard to form, strength, and availability of products uniquely available in Canada but currently not available in the US. Refer also to Dosage forms.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Tablet, Oral, as sodium:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Actonel: 75 mg</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Tablet Delayed Release, Oral, as sodium:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Actonel DR: 35 mg [contains edetate disodium]</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F11441520\" class=\"block meg drugH1Div\"><span class=\"drugH1\">Medication Guide and/or Vaccine Information Statement (VIS)</span>\n    <p style=\"text-indent:0em;display:inline\">An FDA-approved patient medication guide, which is available with the product information and as follows, must be dispensed with this medication:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;\">Actonel: <a target=\"_blank\" href=\"http://www.accessdata.fda.gov/drugsatfda_docs/label/2015/020835s048lbl.pdf#page=38&amp;token=D7XARKVcx4FHonk1KxNy+XWqA+W40myhAh4WjAljg3+lPRFjAPBNa4OImuWL+9OmBn4rPXRD/Qbx+Cd4sSggi3+lGKErV/7iyBhFelpTQI5nMGeaLV1faRUuh/ND8p1g&amp;TOPIC_ID=10242\" target=\"_blank\">http://www.accessdata.fda.gov/drugsatfda_docs/label/2015/020835s048lbl.pdf#page=38</a></p>\n    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;\">Atelvia: <a target=\"_blank\" href=\"http://www.accessdata.fda.gov/drugsatfda_docs/label/2015/022560s007lbl.pdf#page=23&amp;token=zpp8ffTfsRhLy4DDDpqVSzMv2VjwESY3cR3eJERj/dJDu6czA7/FbeyP08X1CpRoLaOOBARMqWG3iGI0acwNJW5Tl5cB8XhZngp+Tae+PsGsMuCUZhHDtDB1jbcY6Ufx&amp;TOPIC_ID=10242\" target=\"_blank\">http://www.accessdata.fda.gov/drugsatfda_docs/label/2015/022560s007lbl.pdf#page=23</a></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F218559\" class=\"block adm drugH1Div\"><span class=\"drugH1\">Administration</span>\n    <p style=\"text-indent:0em;display:inline\">Oral: <b>Note:</b> Avoid administration of oral calcium supplements, antacids, magnesium supplements/laxatives, and iron preparations within 30 minutes of risedronate administration.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Immediate release tablet: Risedronate immediate release tablets must be taken on an empty stomach with a full glass (6 to 8 oz) of <b>plain water</b> (not mineral water) at least 30 minutes before any food, drink, or other medications orally to avoid interference with absorption. Patient must remain sitting upright or standing for at least 30 minutes after taking (to reduce esophageal irritation). Tablet should be swallowed whole; do not crush or chew.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Delayed release tablet: Risedronate delayed release tablets must be taken with at least 4 oz of <b>plain water</b> (not mineral water) immediately after breakfast. Patient must remain sitting upright or standing for at least 30 minutes after taking (to reduce esophageal irritation). Tablet should be swallowed whole; do not cut, split, crush, or chew.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F218558\" class=\"block use drugH1Div\"><span class=\"drugH1\">Use</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Actonel: </i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Osteoporosis:</b> Treatment and prevention of osteoporosis in postmenopausal women; treatment of osteoporosis in men; treatment and prevention of glucocorticoid-induced osteoporosis</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Paget disease:</b> Treatment of Paget disease of the bone</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Atelvia, Actonel DR [Canadian product]: </i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Osteoporosis: </b>Treatment of osteoporosis in postmenopausal women</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F6049623\" class=\"block mst drugH1Div\"><span class=\"drugH1\">Medication Safety Issues</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Sound-alike/look-alike issues: </span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Actonel may be confused with Actos</p>\n        <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Risedronate may be confused with alendronate</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F218548\" class=\"block adr drugH1Div\"><span class=\"drugH1\">Adverse Reactions</span>\n    <p style=\"text-indent:0em;display:inline\">Frequency may vary with product, dose, and indication.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">&gt;10%: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Cardiovascular: Hypertension (11%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Central nervous system: Headache (3% to 18%) </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Dermatologic: Skin rash (8% to 12%) </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Gastrointestinal: Gastrointestinal disease (perforations, ulcers, or bleeding; 51%), diarrhea (5% to 20%), nausea (4% to 13%), abdominal pain (2% to 12%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Genitourinary: Urinary tract infection (11%) </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Infection: Infection (31%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Neuromuscular &amp; skeletal: Arthralgia (7% to 33%), back pain (6% to 28%)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\"> 1% to 10%:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Cardiovascular: Peripheral edema (8%), chest pain (7%), cardiac arrhythmia (2%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Central nervous system: Depression (7%), dizziness (3% to 7%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Endocrine &amp; metabolic: Increased parathyroid hormone (8% to 9%; &gt;1.5 x ULN: &le;2%), hypocalcemia (&le;5%), hypophosphatemia (&lt;3% decrease from baseline)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Gastrointestinal: Dyspepsia (4% to 8%), constipation (3% to 7%), vomiting (2% to 5%), gastritis (1% to 3%), gastroesophageal reflux disease (1% to 2%), duodenitis (&le;1%), glossitis (&le;1%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Genitourinary: Benign prostatic hyperplasia (5%), nephrolithiasis (3%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Hypersensitivity: Acute phase reaction-like symptoms (&le;8%; includes fever, influenza-like illness)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Infection: Influenza (6% to 7%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Neuromuscular &amp; skeletal: Arthropathy (7%), myalgia (1% to 7%), limb pain (2% to 4%), musculoskeletal pain (2%), muscle spasm (1% to 2%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Ophthalmic: Cataract (7%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Respiratory: Flu-like symptoms (10%), pharyngitis (6%), rhinitis (6%), bronchitis (4%), upper respiratory tract infection (3% to 4%)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;text-align:justify;\">&lt;1%, postmarketing, and/or case reports: Abnormal hepatic function tests, angioedema, bullous skin reaction, cough, esophageal ulcer, esophagitis, exacerbation of asthma, femur fracture, gastric ulcer, hypersensitivity reaction, iritis, ostealgia, osteonecrosis (primarily of the jaw), Stevens-Johnson syndrome, toxic epidermal necrolysis, uveitis</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F218562\" class=\"block coi drugH1Div\"><span class=\"drugH1\">Contraindications</span>\n    <p style=\"text-indent:0em;display:inline\">Hypersensitivity to risedronate, bisphosphonates, or any component of the formulation; hypocalcemia; inability to stand or sit upright for at least 30 minutes; abnormalities of the esophagus (eg, stricture, achalasia) which delay esophageal emptying</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F218545\" class=\"block war drugH1Div\"><span class=\"drugH1\">Warnings/Precautions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concerns related to adverse effects:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Bone fractures: Atypical femur fractures have been reported in patients receiving bisphosphonates for treatment/prevention of osteoporosis. The fractures include subtrochanteric femur (bone just below the hip joint) and diaphyseal femur (long segment of the thigh bone). Some patients experience prodromal pain weeks or months before the fracture occurs. It is unclear if bisphosphonate therapy is the cause for these fractures, although the majority of cases have been reported in patients taking bisphosphonates. Patients receiving long-term (&gt;3 to 5 years) therapy may be at an increased risk. Discontinue bisphosphonate therapy in patients who develop a femoral shaft fracture.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Bone/joint/muscle pain: Infrequently, severe (and occasionally debilitating) bone, joint, and/or muscle pain have been reported during bisphosphonate treatment. The onset of pain ranged from a single day to several months. Consider discontinuing therapy in patients who experience severe symptoms; symptoms usually resolve upon discontinuation. Some patients experienced recurrence when rechallenged with same drug or another bisphosphonate; avoid use in patients with a history of these symptoms in association with bisphosphonate therapy.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Gastrointestinal mucosa irritation: May cause irritation to upper gastrointestinal mucosa. Dysphagia, esophagitis, esophageal or gastric ulcers, esophageal erosions, and esophageal stricture (rare) have been reported with oral bisphosphonates; risk increases in patients unable to comply with dosing instructions. Use with caution in patients with dysphagia, esophageal disease, gastritis, duodenitis, or ulcers (may worsen underlying condition). Discontinue if new or worsening symptoms occur.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Osteonecrosis of the jaw: Osteonecrosis of the jaw (ONJ), also referred to as medication-related osteonecrosis of the jaw (MRONJ), has been reported in patients receiving bisphosphonates. Known risk factors for MRONJ include invasive dental procedures (eg, tooth extraction, dental implants, boney surgery), cancer diagnosis, concomitant therapy (eg, chemotherapy, corticosteroids, angiogenesis inhibitors), poor oral hygiene, ill-fitting dentures, and comorbid disorders (anemia, coagulopathy, infection, preexisting dental or periodontal disease). Risk may increase with increased duration of bisphosphonate use. According to a position paper by the American Association of Maxillofacial Surgeons (AAOMS), MRONJ has been associated with bisphosphonate and other antiresorptive agents (denosumab), and antiangiogenic agents (eg, bevacizumab, sunitinib) used for the treatment of osteoporosis or malignancy; risk of MRONJ is significantly higher in cancer patients receiving antiresorptive therapy compared to patients receiving osteoporosis treatment (regardless of medication used or dosing schedule). MRONJ risk is also increased with IV antiresorptive use compared to the minimal risk associated with oral bisphosphonate use, although risk appears to increase with oral bisphosphonates when duration of therapy exceeds 4 years (AAOMS [Ruggiero 2014]). The manufacturer's labeling states that in patients requiring invasive dental procedures, discontinuing bisphosphonates may reduce the risk of ONJ and clinical judgment should guide the decision. However, the AAOMS suggests there is currently no evidence that interrupting oral bisphosphonate therapy alters the risk of ONJ following tooth extraction, and that in patients receiving oral bisphosphonates for &lt;4 years who have no clinical risk factors, no alternations or delay in any procedure common to oral/maxillofacial surgeons, periodontists, and other dental providers is necessary (special considerations apply to patients receiving dental implants). Conversely, in patients receiving oral bisphosphonates for &gt;4 years <b>or</b> in patients receiving oral bisphosphonates for &lt;4 years who have also taken corticosteroids or antiangiogenic medications concomitantly, the AAOMS recommends considering a 2-month drug free period prior to invasive dental procedures (recommendation based on a theoretical benefit) Patients developing ONJ during therapy should receive care by an oral surgeon (AAOMS [Ruggiero 2014]). According to the manufacturer, discontinuation of the bisphosphonate therapy should be considered (based on risk/benefit evaluation) in patients who develop ONJ.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Disease-related concerns:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Glucocorticoid-induced osteoporosis: Evaluate sex steroid hormonal status prior to treatment initiation; consider appropriate hormone replacement if necessary.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hypocalcemia: Before initiation of therapy hypocalcemia must be corrected; ensure adequate calcium and vitamin D intake, especially for patients with Paget disease in whom the pretreatment rate of bone turnover may be greatly elevated.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Renal impairment: Use with caution in patients with renal impairment (not recommended in patients with a CrCl &lt;30 mL/minute).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concurrent drug therapy issues:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Drug-drug interactions: Potentially significant interactions may exist, requiring dose or frequency adjustment, additional monitoring, and/or selection of alternative therapy. Consult drug interactions database for more detailed information.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Special populations:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Pediatric: Not approved for use in pediatric patients with osteogenesis imperfecta due to lack of efficacy in reducing the risk of fracture.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Other warnings/precautions:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Duration of therapy: In the management of osteoporosis, re-evaluate the need for continued therapy periodically; the optimal duration of treatment has not yet been determined. Consider discontinuing after 3 to 5 years of use in patients at low-risk for fracture; following discontinuation, re-evaluate fracture risk periodically.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13300007\" class=\"block cyt drugH1Div\"><span class=\"drugH1\">Metabolism/Transport Effects</span>\n    <p style=\"text-indent:0em;display:inline\">None known.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F218550\" class=\"block dri drugH1Div\"><span class=\"drugH1\">Drug Interactions</span>\n    <br/><br/><div id=\"lexiInteractAddInfo\" class=\"lexi\">(For additional information: <a href=\"https://www.uptodate.com/drug-interactions/?search=&amp;topicId=10242&amp;source=responsive_topic\" class=\"dip\" target=\"_blank\">Launch drug interactions program</a>)</div><div id=\"lexiInteractImgB\" class=\"lexi\"><img src=\"/images/lexiComp/Lexicomp_2012_71x17.gif\" width=\"71\" height=\"17\" border=\"0\"/></div><div class=\"clear\"></div><p style=\"text-indent:-2em;margin-left:2em;\">Aminoglycosides: May enhance the hypocalcemic effect of Bisphosphonate Derivatives.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Angiogenesis Inhibitors (Systemic): May enhance the adverse/toxic effect of Bisphosphonate Derivatives. Specifically, the risk for osteonecrosis of the jaw may be increased.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Antacids: May decrease the serum concentration of Bisphosphonate Derivatives. Management: Avoid administration of antacids containing polyvalent cations within: 2 hours before or after tiludronate/clodronate/etidronate; 60 minutes after oral ibandronate; or 30 minutes after alendronate/risedronate.<b> Exceptions: </b>Magaldrate; Sodium Bicarbonate.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Calcium Salts: May decrease the serum concentration of Bisphosphonate Derivatives. Management: Avoid administration of oral calcium supplements within: 2 hours before or after tiludronate/clodronate/etidronate; 60 minutes after oral ibandronate; or 30 minutes after alendronate/risedronate.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Deferasirox: Bisphosphonate Derivatives may enhance the adverse/toxic effect of Deferasirox. Specifically, the risk for GI ulceration/irritation or GI bleeding may be increased. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Histamine H2 Receptor Antagonists: May increase the serum concentration of Risedronate. This applies specifically to delayed-release risedronate.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Iron Salts: May decrease the serum concentration of Bisphosphonate Derivatives. Management: Avoid administration of oral iron supplements within: 2 hours before or after tiludronate/clodronate/etidronate; 60 minutes after oral ibandronate; or 30 minutes after alendronate/risedronate.<b> Exceptions: </b>Ferric Carboxymaltose; Ferric Gluconate; Ferric Hydroxide Polymaltose Complex; Ferric Pyrophosphate Citrate; Ferumoxytol; Iron Dextran Complex; Iron Isomaltoside; Iron Sucrose.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Magnesium Salts: May decrease the serum concentration of Bisphosphonate Derivatives. Management: Avoid administration of oral magnesium salts within: 2 hours before or after tiludronate/clodronate/etidronate; 60 minutes after oral ibandronate; or 30 minutes after alendronate/risedronate.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Multivitamins/Minerals (with ADEK, Folate, Iron): May decrease the serum concentration of Bisphosphonate Derivatives. Specifically, polyvalent cation-containing multivitamins may decrease the absorption of orally-administered bisphosphonate derivatives. Management: Avoid administration of polyvalent cation-containing multivitamins within: 2 hours before or after tiludronate/clodronate/etidronate; 60 minutes after oral ibandronate; or 30 minutes after alendronate/risedronate.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Multivitamins/Minerals (with AE, No Iron): May decrease the serum concentration of Bisphosphonate Derivatives. Specifically, polyvalent cation-containing multivitamins may decrease the absorption of orally-administered bisphosphonate derivatives. Management: Avoid administration of polyvalent cation-containing multivitamins within: 2 hours before or after tiludronate/clodronate/etidronate; 60 minutes after oral ibandronate; or 30 minutes after alendronate/risedronate.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Nonsteroidal Anti-Inflammatory Agents: May enhance the adverse/toxic effect of Bisphosphonate Derivatives. Both an increased risk of gastrointestinal ulceration and an increased risk of nephrotoxicity are of concern.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Proton Pump Inhibitors: May diminish the therapeutic effect of Risedronate. Proton Pump Inhibitors may increase the serum concentration of Risedronate. This applies specifically to use of delayed-release risedronate.<i> Risk X: Avoid combination</i></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F218578\" class=\"block foi drugH1Div\"><span class=\"drugH1\">Food Interactions</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">Food reduces absorption (similar to other bisphosphonates); mean oral bioavailability is decreased when given with food. Management: Administer immediate release tablet with at least 6 oz of plain water (not mineral water) &ge;30 minutes before the first food or drink of the day other than water. Administer delayed release tablet with at least 4 ounces of plain water immediately after breakfast.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F218552\" class=\"block prf drugH1Div\"><span class=\"drugH1\">Pregnancy Risk Factor</span>\n    <p style=\"text-indent:0em;display:inline\">C (<a href=\"image.htm?imageKey=DRUG%2F50021\" class=\"graphic graphic_table\">show table</a>)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F218565\" class=\"block pri drugH1Div\"><span class=\"drugH1\">Pregnancy Implications</span>\n    <p style=\"text-indent:0em;display:inline\">Adverse events were observed in some animal reproduction studies. It is not known if bisphosphonates cross the placenta, but fetal exposure is expected (Djokanovic 2008; Stathopoulos 2011). Bisphosphonates are incorporated into the bone matrix and gradually released over time. The amount available in the systemic circulation varies by dose and duration of therapy. Theoretically, there may be a risk of fetal harm when pregnancy follows the completion of therapy; however, available data have not shown that exposure to bisphosphonates during pregnancy significantly increases the risk of adverse fetal events (Djokanovic 2008; Levy 2009; Stathopoulos 2011). Until additional data is available, most sources recommend discontinuing bisphosphonate therapy in women of reproductive potential as early as possible prior to a planned pregnancy; use in premenopausal women should be reserved for special circumstances when rapid bone loss is occurring (Bhalla 2010; Pereira 2012; Stathopoulos 2011). Because hypocalcemia has been described following <i>in utero</i> bisphosphonate exposure, exposed infants should be monitored for hypocalcemia after birth (Djokanovic 2008; Stathopoulos 2011).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F218566\" class=\"block brc drugH1Div\"><span class=\"drugH1\">Breast-Feeding Considerations</span>\n    <p style=\"text-indent:0em;display:inline\">It is not known if risedronate is excreted into breast milk. Due to the potential for serious adverse reactions in the nursing infant, the manufacturer recommends a decision be made whether to discontinue nursing or to discontinue the drug, taking into account the importance of treatment to the mother.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F218567\" class=\"block dic drugH1Div\"><span class=\"drugH1\">Dietary Considerations</span>\n    <p style=\"text-indent:0em;display:inline\">Ensure adequate calcium and vitamin D intake; if dietary intake is inadequate, dietary supplementation is recommended. Women and men should consume:</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Calcium: 1,000 mg/day (men: 50 to 70 years) <b>or</b> 1,200 mg/day (women &ge;51 years and men &ge;71 years) (IOM 2011; NOF [Cosman 2014])</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Vitamin D: 800 to 1,000 int. units daily (men and women &ge;50 years) (NOF [Cosman 2014]). Recommended Dietary Allowance (RDA): 600 int. units daily (men and women &le;70 years) <b>or</b> 800 int. units daily (men and women &ge;71 years) (IOM 2011).</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">Take immediate release tablet with at least 6 oz of <b>plain water</b> (not mineral water) &ge;30 minutes before the first food or drink of the day other than water. Take delayed release tablet with at least 4 ounces of <b>plain water</b> immediately <b>after</b> breakfast.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F218554\" class=\"block mop drugH1Div\"><span class=\"drugH1\">Monitoring Parameters</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Osteoporosis: Bone mineral density (BMD) should be evaluated 1 to 2 years after initiating therapy and every 2 years thereafter (NOF [Cosman 2014] in patients with combined risedronate and glucocorticoid treatment, BMD should be made at initiation and repeated after 6 to 12 months; annual measurements of height and weight, assessment of chronic back pain; serum calcium and 25(OH)D; consider measuring biochemical markers of bone turnover </p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;\">Paget disease: Alkaline phosphatase at 6 to 12 weeks for initial response to treatment (when bone turnover will have shown a substantial decline) and potentially at 6 months (maximal suppression of high bone turnover); following treatment completion, monitor at ~6- to 12-month intervals (Singer, 2014); monitoring more specific biochemical markers of bone turnover (eg, serum P1NP, NTX, serum beta-CTx) is generally only warranted in patients with Paget disease who have abnormal liver or biliary tract function or when early assessment of response to treatment is needed (eg, spinal compression, very active disease) (Singer, 2014); serum calcium and 25(OH)D; pain</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F21303673\" class=\"block rer drugH1Div\"><span class=\"drugH1\">Reference Range</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Calcium (total): Adults: 9 to 11 mg/dL (2.05 to 2.54 mmol/L), may slightly decrease with aging</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Phosphorus: 2.5 to 4.5 mg/dL (0.81 to 1.45 mmol/L)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Vitamin D: There is no clear consensus on a reference range for total serum 25(OH)D concentrations or the validity of this level as it relates clinically to bone health. In addition, there is significant variability in the reporting of serum 25(OH)D levels as a result of different assay types in use; however, the following ranges have been suggested:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Adults (IOM, 2011): Sufficient levels in practically all persons: &ge;20 ng/mL (50 nmol/L); concern for risk of toxicity: &gt;50 ng/mL (125 nmol/L)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Osteoporosis patients (NOF [Cosman 2014]): Recommended level to reach and maintain: ~30 ng/mL (75 nmol/L) </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F218544\" class=\"block pha drugH1Div\"><span class=\"drugH1\">Mechanism of Action</span>\n    <p style=\"text-indent:0em;display:inline\">A bisphosphonate which inhibits bone resorption via actions on osteoclasts or on osteoclast precursors; decreases the rate of bone resorption, leading to an indirect increase in bone mineral density. In Paget's disease, characterized by disordered resorption and formation of bone, inhibition of resorption leads to an indirect decrease in bone formation; but the newly-formed bone has a more normal architecture.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F218561\" class=\"block phk drugH1Div\"><span class=\"drugH1\">Pharmacodynamics/Kinetics</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Onset of action: May require weeks </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Absorption: Rapid </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Distribution: V<sub>d</sub>: 13.8 L/kg </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Protein binding: ~24% </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Metabolism: None </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Bioavailability: Poor, ~0.54% to 0.75% </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Half-life elimination: Initial: 1.5 hours; Terminal: 480 to 561 hours</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Time to peak, serum: 1 to 3 hours</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Excretion: Urine (up to 85%); feces (as unabsorbed drug)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F218564\" class=\"block fee drugH1Div\"><span class=\"drugH1\">Pricing: US</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Tablet, EC</b> (Atelvia Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">35 mg (4): $304.93</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Tablet, EC</b> (Risedronate Sodium Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">35 mg (4): $209.21</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Tablets</b> (Actonel Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">5 mg (30): $418.18</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">30 mg (30): $2,925.42</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">35 mg (4): $390.06</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">150 mg (1): $422.50</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Tablets</b> (Risedronate Sodium Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">5 mg (30): $265.67</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">30 mg (30): $1,858.53</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">35 mg (4): $247.81</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">150 mg (1): $233.40</p>\n    <p style=\"text-indent:0em;\">\n      <b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F218568\" class=\"list fbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: International</span>\n    <ul>\n      <li>Acrel (ES);</li>\n      <li>Actonel (AE, AR, AT, AU, BB, BE, BG, BH, BM, BO, BR, BS, BZ, CH, CL, CO, CR, CY, CZ, DE, DO, EC, EE, EG, ES, FR, GB, GR, GT, GY, HK, HN, HR, ID, IE, IL, IT, JM, JO, JP, KR, KW, LB, LU, MT, MX, MY, NI, NL, PA, PE, PL, PR, PT, PY, QA, RO, SG, SI, SR, SV, TH, TR, TT, TW, UY, VE, VN);</li>\n      <li>Actonel Once A Month (ID, IL);</li>\n      <li>Actonel Once A Week (BH, IL, KW, LB, VN, ZA);</li>\n      <li>Actonel once A Week (CY);</li>\n      <li>Actoril (KR);</li>\n      <li>Avestra (SE);</li>\n      <li>Benet (JP);</li>\n      <li>Droriate (PK);</li>\n      <li>Droserid (VN);</li>\n      <li>Gemfos (LK);</li>\n      <li>Gusong (CN);</li>\n      <li>Kantonel (KR);</li>\n      <li>Merval (PY);</li>\n      <li>Norifaz (LV);</li>\n      <li>Optinate (DK, FI, IS, KR, NO, SE);</li>\n      <li>Osteoclax (CO);</li>\n      <li>Osteonate OD (ID);</li>\n      <li>Osteorise (LK);</li>\n      <li>Residron (TH);</li>\n      <li>Retonel (ID);</li>\n      <li>Ribastamin (AR);</li>\n      <li>Ribone (IL);</li>\n      <li>Ridate (IE);</li>\n      <li>Ridbone (KR);</li>\n      <li>Ridbone Month (KR);</li>\n      <li>Ridroqueen (KR);</li>\n      <li>Risedro (AU);</li>\n      <li>Risendros (LV);</li>\n      <li>Risenel (KR);</li>\n      <li>Risenoros (MT);</li>\n      <li>Riseto (KR);</li>\n      <li>Risnel (KR);</li>\n      <li>Risofos (IN);</li>\n      <li>Risonate (IE, LV);</li>\n      <li>Risonato (EC);</li>\n      <li>Risonet (BD);</li>\n      <li>Risontel (IE, MT);</li>\n      <li>Ristonat (ID);</li>\n      <li>Rosenax (VN);</li>\n      <li>Salost (BD);</li>\n      <li>Sedron (BD, KR);</li>\n      <li>Valetta (PK)</li></ul></div>\r\n</div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\">\r\n<li>\r\n<div class=\"reference\">\n    Actonel (risedronate) [prescribing information]. Rockaway, NJ: Warner Chilcott (US) LLC; April 2015.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Actonel and Actonel DR (risedronate) [product monograph]. Markham, Ontario, Canada: Allergan Pharma Co; August 2017.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    American Dental Association Council on Scientific Affairs, &ldquo;Dental Management of Patients Receiving Oral Bisphosphonate Therapy,&rdquo; JADA, 2006, 137(8):1144-50. Available at http://jada.ada.org/article/S0002-8177(14)64960-6/pdf16873332</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Atelvia (risedronate) [prescribing information]. Rockaway, NJ: Warner Chilcott (US) LLC; April 2015.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Author Unknown, &ldquo;Safety Update: Bone-Building Drugs: Risks Explained,,&rdquo; <i>Consum Rep Health</i>, 2006, 18(5):3.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Bhalla AK, &quot;Management of Osteoporosis in a Pre-menopausal Woman,&quot; <i>Best Pract Res Clin Rheumatol</i>, 2010, 24(3):313-27.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/risedronate-drug-information/abstract-text/20534366/pubmed\" target=\"_blank\" id=\"20534366\">20534366</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Cosman F, de Beur SJ, LeBoff MS, et al. Clinician's Guide to Prevention and Treatment of Osteoporosis. <i>Osteoporos Int</i>. 2014;25(10):2359-2381. doi: 10.1007/s00198-014-2794-2.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Djokanovic N, Klieger-Grossmann C, and Koren G, &quot;Does Treatment With Bisphosphonates Endanger the Human Pregnancy?&quot; <i>J Obstet Gynaecol Can</i>, 2008, 30(12):1146-8.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/risedronate-drug-information/abstract-text/19175968/pubmed\" target=\"_blank\" id=\"19175968\">19175968</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Edwards BJ, Hellstein JW, Jacobsen PL, et al, &quot;Updated Recommendations for Managing the Care of Patients Receiving Oral Bisphosphonate Therapy: An Advisory Statement From the American Dental Association Council on Scientific Affairs,&quot; <i> J Am Dent Assoc</i>, 2008, 139(12):1674-7.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/risedronate-drug-information/abstract-text/19047674/pubmed\" target=\"_blank\" id=\"19047674\">19047674</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Filleul O, Crompot E, and Saussez S, &quot;Bisphosphonate-Induced Osteonecrosis of the Jaw: A Review of 2,400 Patient Cases,&quot; <i>J Cancer Res Clin Oncol</i>, 2010, 136(8):1117-24.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/risedronate-drug-information/abstract-text/20508948/pubmed\" target=\"_blank\" id=\"20508948\">20508948</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    French AE, Kaplan N, Lishner M, et al, &ldquo;Taking Bisphosphonates During Pregnancy,&rdquo; <i>Can Fam Physician</i>, 2003, 49:1281-2.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/risedronate-drug-information/abstract-text/14594094/pubmed\" target=\"_blank\" id=\"14594094\">14594094</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Hellstein JW, Adler RA, Edwards B, et al, &quot;Managing the Care of Patients Receiving Antiresorptive Therapy for Prevention and Treatment of Osteoporosis: Executive Summary of Recommendations From the American Dental Association Council on Scientific Affairs,&quot; <i>J Am Dent Assoc</i>, 2011, 142(11):1243-51.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/risedronate-drug-information/abstract-text/22041409/pubmed\" target=\"_blank\" id=\"22041409\">22041409</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Hellstein JW, Adler RA, Edwards B, et al, &quot;Managing the Care of Patients Receiving Antiresorptive Therapy for Prevention and Treatment of Osteoporosis: Recommendations From the American Dental Association Council on Scientific Affairs,&quot; 2011, Available at http://www.ada.org/sections/professionalResources/pdfs/topics_ARONJ_report.pdf. Accessed February 2013.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    IOM (Institute of Medicine), <i>Dietary Reference Intakes for Calcium and Vitamin D,</i> Washington, DC: The National Academies Press, 2011.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Khan AA, Morrison A, Hanley DA, et al. Diagnosis and management of osteonecrosis of the jaw: a systematic review and international consensus. <i>J Bone Miner Res.</i> 2015; 30(1):3-23.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/risedronate-drug-information/abstract-text/25414052/pubmed\" target=\"_blank\" id=\"25414052\">25414052</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Levy S, Fayez I, Taguchi N, et al, &quot;Pregnancy Outcome Following <i>in utero</i> Exposure to Bisphosphonates,&quot; <i>Bone</i>, 2009, 44(3):428-30.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/risedronate-drug-information/abstract-text/19059370/pubmed\" target=\"_blank\" id=\"19059370\">19059370</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Lo JC, O'Ryan FS, Gordon NP, et al, &ldquo;Prevalence of Osteonecrosis of the Jaw in Patients With Oral Bisphosphonate Exposure,&rdquo; <i>J Oral Maxillofac Surg</i>, 2010, 68(2):243-53.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/risedronate-drug-information/abstract-text/19772941/pubmed\" target=\"_blank\" id=\"19772941\">19772941</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    &ldquo;Management of Osteoporosis in Postmenopausal Women: 2010 Position Statement of The North American Menopause Society,&rdquo; <i>Menopause</i>, 2010, 17(1):25-54.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/risedronate-drug-information/abstract-text/20061894/pubmed\" target=\"_blank\" id=\"20061894\">20061894</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Marx RE, Sawatari Y, Fortin M, et al, &ldquo;Bisphosphonate-Induced Exposed Bone (Osteonecrosis/Osteopetrosis) of the Jaws: Risk Factors, Recognition, Prevention, and Treatment,&rdquo; <i>J Oral Maxillofac Surg</i>, 2005, 63(11):1567-75.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/risedronate-drug-information/abstract-text/16243172/pubmed\" target=\"_blank\" id=\"16243172\">16243172</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Mavrokokki T, Cheng A, Stein B, et al, &ldquo;Nature and Frequency of Bisphosphonate-Associated Osteonecrosis of the Jaws in Australia,&rdquo; <i>J Oral Maxillofac Surg</i>, 2007, 65(3):415-23.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/risedronate-drug-information/abstract-text/17307586/pubmed\" target=\"_blank\" id=\"17307586\">17307586</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Pereira RM, Carvalho JF, Paula AP, et al, &quot;Guidelines for the Prevention and Treatment of Glucocorticoid-Induced Osteoporosis,&quot; <i>Rev Bras Reumatol</i>, 2012, 52(4):580-93.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/risedronate-drug-information/abstract-text/22885424/pubmed\" target=\"_blank\" id=\"22885424\">22885424</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Ralston SH, &ldquo;Pathogenesis of Paget's Disease of Bone,&rdquo; <i>Bone</i>, 2008, 43(5):819-25.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/risedronate-drug-information/abstract-text/18672105/pubmed\" target=\"_blank\" id=\"18672105\">18672105</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Ruggiero SL, Dodson TB, Fantasia J, et al; American Association of Oral and Maxillofacial Surgeons. American Association of Oral and Maxillofacial Surgeons position paper on medication-related osteonecrosis of the jaw--2014 update. <i>J Oral Maxillofac Surg</i>. 2014;72(10):1938-1956. doi: 10.1016/j.joms.2014.04.031.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/risedronate-drug-information/abstract-text/25234529/pubmed\" target=\"_blank\" id=\"25234529\">25234529</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Ruggiero S, Gralow J, Marx RE, et al, &quot;Practical Guidelines for the Prevention, Diagnosis, and Treatment of Osteonecrosis of the Jaw in Patients With Cancer,&quot; <i>J Clin Oncol</i>, 2006, 2(1):7-14.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Sellmeyer DE, &ldquo;Atypical Fractures as a Potential Complication of Long-term Bisphosphonate Therapy,&rdquo; <i>JAMA</i>, 2010, 304(13):1480-4.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/risedronate-drug-information/abstract-text/20924014/pubmed\" target=\"_blank\" id=\"20924014\">20924014</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Shane E, Burr D, Ebeling PR, et al, &ldquo;Atypical Subtrochanteric and Diaphyseal Femoral Fractures: Report of a Task Force of the American Society for Bone and Mineral Research,&rdquo; <i>J Bone Miner Res</i>, 2010, 25(11):2267-94.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/risedronate-drug-information/abstract-text/20842676/pubmed\" target=\"_blank\" id=\"20842676\">20842676</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Singer FR, Bone HG, Hosking DJ, et al. Paget's disease of bone: an Endocrine Society clinical practice guideline. <i>J Clin Endocrinol Metab</i>. 2014;99(12):4408-4422.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/risedronate-drug-information/abstract-text/25406796/pubmed\" target=\"_blank\" id=\"25406796\">25406796</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Stathopoulos IP, Liakou CG, Katsalira A, et al, &quot;The Use of Bisphosphonates in Women Prior to or During Pregnancy and Lactation,&quot; <i>Hormones (Athens)</i>, 2011, 10(4):280-91.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/risedronate-drug-information/abstract-text/22281884/pubmed\" target=\"_blank\" id=\"22281884\">22281884</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Whyte MP, &ldquo;Clinical Practice. Paget's Disease of Bone,&rdquo; <i>N Engl J Med</i>, 2006, 355(6):593-600.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/risedronate-drug-information/abstract-text/16899779/pubmed\" target=\"_blank\" id=\"16899779\">16899779</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Wysowski DK, &ldquo;Reports of Esophageal Cancer With Oral Bisphosphonate Use,&rdquo; <i>N Engl J Med</i>, 2009, 360(1):89-90.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/risedronate-drug-information/abstract-text/19118315/pubmed\" target=\"_blank\" id=\"19118315\">19118315</a>]</span></div>\r\n</li></ol></div><div id=\"topicVersionRevision\">Topic 10242 Version 176.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul><li class=\"plainItem\"><a sectionName=\"Brand Names: US\" href=\"#F218582\" class=\"outlineLink\">Brand Names: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: Canada\" href=\"#F218583\" class=\"outlineLink\">Brand Names: Canada</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacologic Category\" href=\"#F218606\" class=\"outlineLink\">Pharmacologic Category</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Adult\" href=\"#F218586\" class=\"outlineLink\">Dosing: Adult</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Geriatric\" href=\"#F218587\" class=\"outlineLink\">Dosing: Geriatric</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Renal Impairment\" href=\"#F218588\" class=\"outlineLink\">Dosing: Renal Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Hepatic Impairment\" href=\"#F9565124\" class=\"outlineLink\">Dosing: Hepatic Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms\" href=\"#F218556\" class=\"outlineLink\">Dosage Forms</a></li><li class=\"plainItem\"><a sectionName=\"Generic Equivalent Available (US)\" href=\"#F218541\" class=\"outlineLink\">Generic Equivalent Available (US)</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms: Canada\" href=\"#F46548992\" class=\"outlineLink\">Dosage Forms: Canada</a></li><li class=\"plainItem\"><a sectionName=\"Medication Guide and/or Vaccine Information Statement (VIS)\" href=\"#F11441520\" class=\"outlineLink\">Medication Guide and/or Vaccine Information Statement (VIS)</a></li><li class=\"plainItem\"><a sectionName=\"Administration\" href=\"#F218559\" class=\"outlineLink\">Administration</a></li><li class=\"plainItem\"><a sectionName=\"Use\" href=\"#F218558\" class=\"outlineLink\">Use</a></li><li class=\"plainItem\"><a sectionName=\"Medication Safety Issues\" href=\"#F6049623\" class=\"outlineLink\">Medication Safety Issues</a></li><li class=\"plainItem\"><a sectionName=\"Adverse Reactions\" href=\"#F218548\" class=\"outlineLink\">Adverse Reactions</a></li><li class=\"plainItem\"><a sectionName=\"Contraindications\" href=\"#F218562\" class=\"outlineLink\">Contraindications</a></li><li class=\"plainItem\"><a sectionName=\"Warnings/Precautions\" href=\"#F218545\" class=\"outlineLink\">Warnings/Precautions</a></li><li class=\"plainItem\"><a sectionName=\"Metabolism/Transport Effects\" href=\"#F13300007\" class=\"outlineLink\">Metabolism/Transport Effects</a></li><li class=\"plainItem\"><a sectionName=\"Drug Interactions\" href=\"#F218550\" class=\"outlineLink\">Drug Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Food Interactions\" href=\"#F218578\" class=\"outlineLink\">Food Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Risk Factor\" href=\"#F218552\" class=\"outlineLink\">Pregnancy Risk Factor</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Implications\" href=\"#F218565\" class=\"outlineLink\">Pregnancy Implications</a></li><li class=\"plainItem\"><a sectionName=\"Breast-Feeding Considerations\" href=\"#F218566\" class=\"outlineLink\">Breast-Feeding Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Dietary Considerations\" href=\"#F218567\" class=\"outlineLink\">Dietary Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Monitoring Parameters\" href=\"#F218554\" class=\"outlineLink\">Monitoring Parameters</a></li><li class=\"plainItem\"><a sectionName=\"Reference Range\" href=\"#F21303673\" class=\"outlineLink\">Reference Range</a></li><li class=\"plainItem\"><a sectionName=\"Mechanism of Action\" href=\"#F218544\" class=\"outlineLink\">Mechanism of Action</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacodynamics/Kinetics\" href=\"#F218561\" class=\"outlineLink\">Pharmacodynamics/Kinetics</a></li><li class=\"plainItem\"><a sectionName=\"Pricing: US\" href=\"#F218564\" class=\"outlineLink\">Pricing: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: International\" href=\"#F218568\" class=\"outlineLink\">Brand Names: International</a></li><li class=\"plainItem\"><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DRUG_GEN/10242|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=DRUG/57469\" class=\"graphic graphic_table\">- Lexicomp clinical abbreviations</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li><a href=\"topic.htm?path=risedronate-patient-drug-information\" class=\"drug drug_patient\">Risedronate: Patient drug information</a></li></ul></div></div>","javascript":null}